-

05:36:03 PM

NBIO Stock News

NBIO - Nascent Biotech Inc

01/25/23 8:00 AM

OTC : NBIO

clinical trial

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of

RHEA-AI

neutral

01/10/23 8:00 AM

OTC : NBIO

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion and

RHEA-AI

neutral

12/20/22 8:00 AM

OTC : NBIO

management

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting the treatment of various cancers, announced today that Dr. Ivan Babic, a renowned

RHEA-AI

neutral

11/01/22 8:00 AM

OTC : NBIO

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal antibodies targeting treatment of various cancers, announced today that the United States Patent and

RHEA-AI

neutral

10/04/22 8:00 AM

OTC : NBIO

clinical trial

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company has

RHEA-AI

neutral

09/13/22 8:00 AM

OTC : NBIO

clinical trial

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion of the

RHEA-AI

neutral

07/19/22 8:00 AM

OTC : NBIO

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

06/07/22 8:00 AM

OTC : NBIO

clinical trial

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

05/04/22 8:00 AM

OTC : NBIO

Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO,

RHEA-AI

very positive

04/12/22 8:00 AM

OTC : NBIO

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS). Nascent is exploring the potential

RHEA-AI

neutral